Bristol-Myers Squibb Co.

Company Snapshot

Founded: 1887
Entity Type: Public
Employees: 34,100
Region: U.S.
Revenue: $48,300.0 Millions
Revenue Year: 2024
Segment: Elquis
Headquarter: New York, U.S.
Key Geographics: U.S., Other Regions
Corporate Address: Route 206 & Province Line Road Princeton, New Jersey 08543 U.S. Tel: +1-609-252-4621 www.bms.com

Company Overview

Bristol Myers Squibb Co. is a global biopharmaceutical company. The drug manufacturing company focuses on cardiovascular, anti-infective, and anticancer therapies. It undertakes the discovery, development, licensing, manufacture, marketing, and distribution of biopharmaceuticals and related healthcare products.

The company also focuses on psychiatric disorders, diabetes, hepatitis B, HIV/AIDS, and rheumatoid arthritis. Its products are sold to wholesalers, hospitals, retail pharmacies, and government entities. The company operates in a single segment, i.e., discovering, developing, licensing, manufacturing, marketing, distributing, and selling innovative medicines that help patients with serious diseases.

BMS operates R&D facilities in the U.S., Belgium, England, France, and Japan. Manufacturing facilities are in Puerto Rico, the U.S., France, Italy, Ireland, Japan, Mexico, and China. Bristol Myers Squibb’s Genome Biology and Emerging Technologies group evaluates and develops emerging genomic-engineering technologies for the drug discovery workflow.

Bristol-Myers Squibb Co. In Reports

Immunotherapy Drugs: Global Markets

Our Research report provides an overview of the immunotherapy drugs market report analyzes the market trends of immunotherapy drugs with data from 2024, estimates from 2025, projections of compound annual growth rates...

Biological Therapies for Cancer: Technologies and Global Markets

According to our research analyst biological therapies for cancer market includes global revenue ($ Million) for the base year data of 2024 and estimated data for the forecast period 2025 through 2030.

Fusion Proteins: Global Market

Our detailed report on the fusion protein market and analyzes trends It includes global revenue ($ Million) for the base year 2024, estimated data for 2025.

Company's Business Segments

  • In-Line Products : Elquis, Opdivo, Pomalyst, Orencia, Sprycel, Yervoy, Empliciti, Mature and Other Brands
  • New product portfolio : Reblozyl, Abecma, Opdualag, Zeposia, Breyanzi, Onureg, Inrebic, Canzyos and Sotyktu
  • Recent LOE Products : Revlimid and Abraxane

Applications/End User Industries

  • Oncology
  • Innovative Treatments
  • Cancer
  • Immunotherapy
  • Therapies
  • Cardiovascular Diseases
  • Immunological Disorders
  • Fibrotic Diseases
  • Melanoma
  • Renal Cell Carcinoma
  • Atrial Fibrillation
  • Pulmonary Embolism
  • Lymphoma
  • Rheumatoid Arthritis
  • Myelodysplastic
  • Schizophrenia
AI: Your Say